Although Crm1 is overexpressed in various types of human cancer, including glioma, cervical cancer and renal cell carcinoma, and has the potential to be a prognostic marker for cancer (14–16), the clinical relevance of NXF3 in human cancer remains undetermined. This evidence concerns the gene NXF3 and central nervous system cancer.